OTC AM
300 Vesey Street, 12th Floor, New York, NY, 10282, United States
Overview
OTC Markets Group Inc. (OTCQX: OTCM) operates the world's largest electronic marketplace for broker-dealers to trade unlisted stocks. OTC Markets Group's OTC Link™ platform supports an open network of competing broker-dealers that provide investors with the best prices in over 10,000 OTC securities. OTC Markets Group categorizes the wide spectrum of OTC-traded companies into three tiers - OTCQX (the quality-controlled marketplace for investor friendly companies), OTCQB (the U.S. reporting company marketplace for development stage companies), and OTC Pink (the speculative trading marketplace) - so investors can identify the level and quality of information companies provide.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 1
- Active investors
- 4
Sector focus
- Financial Services
- Marketplace
Investment portfolio
- Receipts Depositary Corporation
Participated · Equity · Jun 2026
Receipts Depositary Corporation is a Houston‑based depositary that issues depositary receipts (DRs) designed to let investors own digital and alternative assets through regulated, market‑eligible instruments. Its offerings provide issuer services, operational infrastructure, and market connectivity to connect asset issuers, intermediaries, and U.S. capital markets. The founders bring more than a decade of experience in the DR business, and the company states it is building a modern, technology‑driven depositary platform. RDC plans to expand its suite of DR products across additional asset categories and make certain offerings available to retail investors. The company is investing in capital markets infrastructure, go‑to‑market expansion, and strategic hiring to support upcoming product launches. RDC notes it is not a bank and is not registered as a broker, dealer, or investment adviser in any jurisdiction. The company recently raised $7 million to support these initiatives.
- Biom'Up
Participated · Series C · Sep 2015
Biom'Up develops a new generation hemostatic product, HEMOBLAST TM, and markets proprietary collagen-based products including COVA TM, COVAMESH TM and MATRITM BONE. The company focuses on absorbable medical devices for use in biosurgery. Management is led by CEO Étienne Binant. Biom'Up reported turnover of more than €3m in 2014 and expected over 30% sales growth for its existing product portfolio in 2015. The company plans to use new funds to further develop HEMOBLAST TM, specifically to support its clinical study activities in Europe and North America. Operations are based in Saint-Priest, France. Biom'Up designs, develops and manufactures re-absorbable medical implants for a range of surgical applications from nerve regeneration to cardio-thoracic surgery. Its marketed products include COVA, a membrane for prevention of adhesions and controlled healing available in Europe and the US, and MATRI BONE, a bone regeneration matrix sold in Europe. The company employs 27 people, including eight engineers and three doctors. Biom'Up plans to use new funding to strengthen its sales team to accelerate domestic and export roll-out and to finance a phase III clinical trial in Europe and the US for a new product range targeting major surgery and regenerative medicine markets. It has initiated a US development strategy by filing initial 510(k) applications with the FDA and establishing a multidisciplinary scientific advisory board of opinion leaders in France and the US. Founded in 2005 and based in Lyon, France, Biom'Up is focused on advancing its clinical pipeline and commercial expansion.